Novartis targets 5%-6% annual sales growth until 2030 on key cancer drugs [CNBC]
Avidity Biosciences, Inc. (RNA)
Company Research
Source: CNBC
peak-revenue prospects for its cancer drugs Kisqali and Scemblix to offset losses from expiring patents. In a statement ahead of an investor event, the company lifted the peak sales forecast for Kisqali, used to treat a common type of breast cancer, to at least $10 billion from a previous estimate of $8 billion. For leukaemia drug Scemblix, Novartis now expects peak sales of at least $4 billion, up from at least $3 billion. The company said its eight most promising approved drugs each carry peak-sales potential of $3 billion to $10 billion. Last month, it moved to acquire Avidity Biosciences in a $12 billion deal to add muscle-disorder treatment candidates, part of a broader push to offset declining sales of established products, including its heart-failure drug Entresto. The company has said the planned acquisition would lift its projected annual sales growth for 2024–2029 to 6%, up from the previously expected 5%. The pharma major said on Thursday it is targeting a core
Show less
Read more
Impact Snapshot
Event Time:
RNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNA alerts
High impacting Avidity Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RNA
News
- Avidity Biosciences, Inc. (RNA): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-WTRG, RNA, FIZN, and TCBXPR Newswire
- Novartis sees sales boost from key cancer drugs [Yahoo! Finance Canada]Yahoo! Finance Canada
- Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44PR Newswire
- Avidity Biosciences (NASDAQ:RNA) had its "hold" rating reaffirmed by analysts at Cowen Inc.MarketBeat
RNA
Earnings
- 11/10/25 - Miss
RNA
Sec Filings
- 12/5/25 - Form SCHEDULE
- 11/24/25 - Form PREM14A
- 11/20/25 - Form DEFA14A
- RNA's page on the SEC website